Sinenhlanhla Mthembu | Cardiovascular | Young Scientist Award

Posted on by sciencefather

Ms. Sinenhlanhla Mthembu | Cardiovascular | Young Scientist Award

đŸ‘€Â Ms. Sinenhlanhla Mthembu, North-West University, South Africa

Sinenhlanhla Xoliswa Happiness Mthembu is a PhD candidate in Biochemistry at North-West University, specializing in dyslipidemia-associated myocardial dysfunction and cardioprotective effects of natural compounds like aspalathin and sulforaphane. With a strong foundation in Biochemistry and Microbiology, Sinenhlanhla has contributed significantly to the understanding of mitochondrial bioenergetics, oxidative stress, and metabolic diseases, especially related to cardiovascular health. Her research and dedication have earned her several prestigious awards and recognitions, such as the IUBMB MilliporeSigma ENABLE-Africa Fellowship and the South African Women in Science Award. She is a member of the South African Society of Biochemistry and Molecular Biology and the South African Heart Association.

Professional Profile 

Scopus 

Orcid

Google Scholar

🌟  Suitability for the Award Research for Young Scientist Award

Sinenhlanhla Xoliswa Happiness Mthembu stands out as an ideal candidate for the Research for Young Scientist Award, owing to her impressive academic trajectory and pioneering contributions to the field of Biochemistry and Microbiology. Her current doctoral research on dyslipidemia-associated dysregulations and cardioprotective effects of aspalathin and sulforaphane, pursued at North-West University, is highly relevant and demonstrates a deep understanding of biochemical and mitochondrial bioenergetics. She has made significant strides in understanding the role of mitochondrial function in various diseases, especially in relation to cardiovascular and metabolic disorders, which showcases her scientific rigor.

In addition to her doctoral work, Mthembu has contributed extensively to scientific knowledge through numerous publications in renowned journals. Her research on the potential therapeutic roles of bioactive compounds like aspalathin and sulforaphane aligns with global health concerns, particularly in the areas of obesity, diabetes, and cardiovascular diseases. This breadth of work places her at the forefront of emerging research on metabolic diseases and therapeutic interventions.

🎓 Education 

Sinenhlanhla Mthembu’s educational journey reflects her dedication to advancing the field of Biochemistry. She completed her MSc in Biochemistry at the University of Zululand, where she explored the effect of Rooibos Polyphenols on mitochondrial function in skeletal muscles. Her undergraduate studies in Biochemistry and Microbiology laid a solid foundation for her research in molecular biology. She is currently pursuing a PhD at North-West University, investigating the cardioprotective effects of aspalathin and sulforaphane in the context of dyslipidemia. Her academic pursuits demonstrate a keen focus on cardiovascular health, oxidative stress, and mitochondrial bioenergetics, establishing her as a rising star in the scientific community.

đŸ’ŒÂ Â Professional Experience 

Sinenhlanhla Mthembu’s professional journey is marked by her current role as a PhD intern fellow at the South African Medical Research Council (SAMRC), where she investigates the impact of dyslipidemia and metabolic diseases on heart function. Her previous experience as a laboratory assistant and demonstrator at North-West University further enhanced her expertise in molecular biology, biochemistry, and scientific research techniques. She has worked extensively with techniques such as RT-qPCR, Western blot analysis, flow cytometry, and Seahorse XF technology. Throughout her career, Sinenhlanhla has contributed to the development of therapeutic approaches to tackle diabetes, obesity, and cardiovascular diseases.

🏅 Awards and Recognition 

Sinenhlanhla Mthembu’s excellence has been recognized with numerous awards and scholarships. She received the IUBMB MilliporeSigma ENABLE-Africa Fellowship in 2024, along with the South African Women in Science Award, which underscores her contributions to advancing women in science. Her outstanding presentation at the FEBS-IUBMB-ENABLE conference earned her the Outstanding Poster Award. Sinenhlanhla was also granted the SA Heart Congress Educational Grant to attend the 24th Annual SA Heart Congress. She has been awarded the SAMRC Scholarship Programme for both her PhD and MSc studies and has received the prestigious Top Achiever award from the Moses Kotane Institute and the University of Zululand.

🌍  Research Skills On Cardiovascular

Sinenhlanhla Mthembu possesses an array of advanced research skills, with a strong focus on Biochemistry and Molecular Biology. Her expertise includes Metagenomics sequencing, RT-qPCR, Western blot analysis, and flow cytometry. She has experience in scientific peer review and writing, as well as cell culture techniques. Sinenhlanhla is proficient in utilizing Seahorse XF technology and ELISA assays to evaluate metabolic changes at the cellular level. Her research focuses on dyslipidemia, mitochondrial dysfunction, oxidative stress, and the role of natural compounds like aspalathin and sulforaphane in combating metabolic diseases, particularly cardiovascular complications.

📖 Publication Top Notes

  • Rutin ameliorates inflammation and improves metabolic function: A comprehensive analysis of scientific literature
    Authors: N Muvhulawa, PV Dludla, K Ziqubu, SXH Mthembu, F Mthiyane, …
    Citation: Pharmacological research 178, 106163
    Year: 2022
  • Detrimental effects of lipid peroxidation in type 2 diabetes: Exploring the neutralizing influence of antioxidants
    Authors: SC Shabalala, R Johnson, AK Basson, K Ziqubu, N Hlengwa, …
    Citation: Antioxidants 11 (10), 2071
    Year: 2022
  • A Review on the Antidiabetic Properties of Moringa oleifera Extracts: Focusing on Oxidative Stress and Inflammation as Main Therapeutic Targets
    Authors: FT Mthiyane, PV Dludla, K Ziqubu, SXH Mthembu, N Muvhulawa, …
    Citation: Frontiers in Pharmacology 13, 940572
    Year: 2022
  • An insight into brown/beige adipose tissue whitening, a metabolic complication of obesity with the multifactorial origin
    Authors: K Ziqubu, PV Dludla, SXH Mthembu, BB Nkambule, SE Mabhida, BU Jack, …
    Citation: Frontiers in Endocrinology 14, 1114767
    Year: 2023
  • Anti-obesity effects of metformin: a scoping review evaluating the feasibility of brown adipose tissue as a therapeutic target
    Authors: K Ziqubu, SE Mazibuko-Mbeje, SXH Mthembu, SE Mabhida, BU Jack, …
    Citation: International Journal of Molecular Sciences 24 (3), 2227
    Year: 2023
  • Impact of physical exercise and caloric restriction in patients with type 2 diabetes: Skeletal muscle insulin resistance and mitochondrial dysfunction as ideal therapeutic targets
    Authors: SXH Mthembu, SE Mazibuko-Mbeje, K Ziqubu, TA Nyawo, N Obonye, …
    Citation: Life Sciences 297, 120467
    Year: 2022
  • Physical exercise potentially targets epicardial adipose tissue to reduce cardiovascular disease risk in patients with metabolic diseases: Oxidative stress and inflammation
    Authors: TA Nyawo, C Pheiffer, SE Mazibuko-Mbeje, SXH Mthembu, …
    Citation: Antioxidants 10 (11), 1758
    Year: 2021
  • Impact of isoorientin on metabolic activity and lipid accumulation in differentiated adipocytes
    Authors: K Ziqubu, CJF Muller, PV Dludla, SXH Mthembu, N Obonye, J Louw, …
    Citation: Molecules 25 (8), 1773
    Year: 2020
  • A systematic review exploring the significance of measuring epicardial fat thickness in correlation to B-type natriuretic peptide levels as prognostic and diagnostic markers in
    Authors: TA Nyawo, PV Dludla, SE Mazibuko-Mbeje, SXH Mthembu, …
    Citation: Heart Failure Reviews, 1-11
    Year: 2022
  • Rooibos flavonoids, aspalathin, isoorientin, and orientin ameliorate antimycin A-induced mitochondrial dysfunction by improving mitochondrial bioenergetics in cultured skeletal
    Authors: SXH Mthembu, CJF Muller, PV Dludla, E Madoroba, AP Kappo, …
    Citation: Molecules 26 (20), 6289
    Year: 2021

 

Alberto Esteban FernĂĄndez | MiocardiopatĂ­as | Best Researcher Award

Posted on by sciencefather

Assoc. Prof. Dr. Alberto Esteban FernĂĄndez | MiocardiopatĂ­as | Best Researcher Award

đŸ‘€Â Assoc. Prof. Dr. Alberto Esteban FernĂĄndez, Hospital Universitario Severo Ochoa, Spain

Alberto Esteban FernĂĄndez, born in Valladolid on July 4, 1984, is a distinguished cardiologist and expert in heart failure, particularly in the field of myocardial diseases. With a career spanning both clinical and academic settings, Dr. FernĂĄndez has made significant contributions to research and clinical practice in cardiology. He currently holds positions as a specialist in heart failure at the Hospital Universitario Severo Ochoa and as a tutor for cardiology residents. With extensive international experience, he has collaborated with the European Society of Cardiology and several esteemed research centers. Dr. FernĂĄndez is dedicated to advancing the treatment of dilated cardiomyopathy and heart failure through innovative research and clinical care. He also plays an active role in several medical committees and ethical boards. In addition to his clinical expertise, he is a passionate educator, mentoring the next generation of cardiologists.

Professional Profile

Scopus

Orcid

Google Scholar

🌟 Suitability for the “Research for Best Researcher Award”

Alberto Esteban FernĂĄndez is an exceptional candidate for the “Research for Best Researcher Award” due to his extensive background in cardiology, particularly in heart failure, and his remarkable contributions to both clinical practice and research. He holds a Doctorate in Medicine from the University of Navarra, where his thesis on cardiac magnetic resonance imaging in ischemic heart disease showcased his expertise and commitment to advancing the field. Furthermore, his postdoctoral experience, including a research fellowship at the BHF Cardiovascular Research Centre, demonstrates his capacity to engage in high-level scientific inquiry.

His qualifications, including multiple master’s degrees, certifications in cardiology, and advanced heart failure, reflect his continuous pursuit of knowledge and professional growth. Notably, his role as a leading specialist in advanced heart failure and his leadership in cardiology departments at prominent hospitals, such as the Hospital Universitario Severo Ochoa and the Hospital Universitario de MĂłstoles, underline his ability to merge clinical excellence with research, creating impactful contributions to healthcare.

🎓 Education

Dr. Alberto Esteban FernĂĄndez’s academic journey is marked by a series of prestigious qualifications. He is currently pursuing a Master’s in Statistics in Health Sciences at the University of Barcelona. He earned an Expert University Degree in Family Cardiopathies from the University Francisco de Vitoria in 2021. Dr. FernĂĄndez also holds multiple advanced certifications, including the European Society of Cardiology’s HFA Certification in Heart Failure (2020), and a Doctorate in Medicine from the University of Navarra (2019), where he received the Outstanding Cum Laude distinction. His doctoral thesis focused on the use of cardiac magnetic resonance imaging in detecting myocardial ischemia. Furthermore, he completed a Master’s in Health Research Methodology at the University of Salamanca and postgraduate studies in various cardiology specialties. His academic credentials are complemented by numerous certifications in advanced cardiac care and specialized heart failure treatment, demonstrating his commitment to excellence in the medical field.

Â đŸ’ŒÂ Â Professional Experience

Dr. Alberto Esteban FernĂĄndez has an extensive professional background, primarily in cardiology with a focus on heart failure. He is currently a Specialist at the Hospital Universitario Severo Ochoa, where he manages the heart failure unit. He has previously held key roles at the Hospital Universitario de MĂłstoles, where he led the heart failure unit, and at various other prestigious institutions, including the Hospital ClĂ­nico Universitario San Carlos in Madrid. Additionally, Dr. FernĂĄndez has served as a scientific editor for the Spanish Society of Cardiology’s blog and Cardioteca, contributing to the dissemination of cutting-edge research. His international experience includes fellowships at the Golden Jubilee National Hospital and the University of Glasgow, where he advanced his expertise in heart failure and transplantation. As a clinical and academic leader, Dr. FernĂĄndez is also involved in several cardiology committees and actively contributes to the medical community through teaching and mentorship.

🏅 Awards and Recognition

Dr. Alberto Esteban FernĂĄndez has received numerous accolades throughout his career, reflecting his contributions to the field of cardiology. He holds the prestigious Doctorate in Medicine from the University of Navarra, awarded with the highest distinction, Cum Laude. His work in heart failure and myocardial diseases has been recognized by the European Society of Cardiology, where he holds several certifications. Dr. FernĂĄndez was also appointed to the Heart Failure Association of the European Society of Cardiology’s committees, where he continues to influence the direction of clinical practice. He has been recognized as a leader in his field by his peers and is a key figure in Spanish cardiology. His efforts in advancing research, patient care, and medical education have earned him a reputation as one of the foremost experts in heart failure treatment and management.

🌍 Research Skills On Miocardiopatías

Dr. Alberto Esteban Fernández is a highly skilled researcher with a focus on heart failure, myocardial diseases, and advanced cardiology techniques. His research expertise spans cardiac magnetic resonance imaging, risk stratification in heart failure, and the genetic components of cardiomyopathies. Dr. Fernández’s doctoral thesis on cardiac stress imaging for myocardial ischemia detection contributed significantly to clinical practice and research. He is adept at designing and executing clinical trials and observational studies, particularly in the context of heart failure and cardiomyopathy. Dr. Fernández has published numerous articles in high-impact journals and has presented his research at international conferences, where his work is widely recognized. His research is supported by his clinical experience, ensuring that his studies are grounded in real-world applications. Additionally, he collaborates with various research institutions and participates in international studies, contributing to the advancement of cardiology research.

📖 Publication Top Notes

  • Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation
    Authors: N Calvo, N Salterain, H Arguedas, A Macias, A Esteban, …
    Citation: Ep Europace 17 (10), 1533-1540
    Year: 2015
  • In-hospital mortality and readmissions for heart failure in Spain. A Study of Index Episodes and 30-Day and 1-year Cardiac Readmissions
    Authors: PM Santos, RB Freire, AE FernĂĄndez, JLB Sobrino, CF PĂ©rez, …
    Citation: Revista Española de Cardiología (English Edition) 72 (12), 998-1004
    Year: 2019
  • Sacubitril/valsartan in daily clinical practice: data from a prospective registry
    Authors: L Vicent, A Esteban-FernĂĄndez, M GĂłmez-Bueno, J De-Juan, …
    Citation: Journal of Cardiovascular Pharmacology 73 (2), 118-124
    Year: 2019
  • Frailty and prognosis of older patients with chronic heart failure
    Authors: C JimĂ©nez-MĂ©ndez, P DĂ­ez-Villanueva, C Bonanad, C Ortiz-CortĂ©s, …
    Citation: Revista Española de Cardiología (English Edition) 75 (12), 1011-1019
    Year: 2022
  • Consensus document and recommendations on palliative care in heart failure of the Heart Failure and Geriatric Cardiology Working Groups of the Spanish Society of Cardiology
    Authors: JMG Pinilla, P DĂ­ez-Villanueva, RB Freire, F Formiga, MC Marcos, …
    Citation: Revista Española de Cardiología (English Edition) 73 (1), 69-77
    Year: 2020
  • Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
    Authors: JC LĂłpez‐Azor, L Vicent, MJ Valero‐Masa, A Esteban‐FernĂĄndez, …
    Citation: ESC Heart Failure 6 (6), 1161-1166
    Year: 2019
  • Sex influence on the efficacy and safety of sacubitril/valsartan
    Authors: L Vicent, A Ayesta, A Esteban-FernĂĄndez, M GĂłmez-Bueno, J De-Juan, …
    Citation: Cardiology 142 (2), 73-78
    Year: 2019
  • Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort
    Authors: A Esteban-FernĂĄndez, P DĂ­ez-Villanueva, L Vicent, R Bover, …
    Citation: Revista Espanola de Geriatria y Gerontologia 55 (2), 65-69
    Year: 2020
  • Mortalidad hospitalaria y reingresos por insuficiencia cardiaca en España. Un estudio de los episodios Ă­ndice y los reingresos por causas cardiacas a los 30 dĂ­as y al año
    Authors: PM Santos, RB Freire, AE FernĂĄndez, JLB Sobrino, CF PĂ©rez, …
    Citation: Revista Española de Cardiología 72 (12), 998-1004
    Year: 2019
  • Clinical profile of a nonselected population treated with sacubitril/valsartan is different from PARADIGM-HF trial
    Authors: L Vicent, A Esteban-Fernandez, M Gomez-Bueno, J De-Juan, …
    Citation: Journal of Cardiovascular Pharmacology 72 (2), 112-116
    Year: 2018